通过数字宣传进行物质使用障碍教育:对计划传播和实施的评估
Journal of the American Pharmacists Association : JAPhA
|November 6, 2025
概括
阿拉巴马州的一项基于网络的计划有效地教育了医疗保健专业人员和公众关于物质使用障碍 (SUD) 的知识. 该倡议达到了数百万,证明了数字推广和持续教育激励措施的力量,以提高SUD的意识和干预.
科学领域:
- 公共卫生 公共卫生
- 数字健康教育 数字健康教育
- 药物使用障碍 药物使用障碍
背景情况:
- 药物使用障碍 (SUD) 是阿拉巴马州的一个主要公共卫生问题,其比率超过了全国平均水平.
- 弱势群体在获得护理方面面临重大障碍,包括耻辱和不平等的接入.
- 对于医疗保健专业人员和普通公众来说,急需可扩展,可访问的教育干预措施.
研究的目的:
- 设计,传播和实施一个基于网络的教育计划,阿拉巴马州物质使用障碍 (SUDA) 计划.
- 为了解决阿拉巴马州关键受众中新出现的物质使用趋势.
- 提供可访问的关于阿片类药物使用障碍,兴奋剂滥用和vaping的教育.
主要方法:
- 通过奥本大学和阿拉巴马州心理健康部门的合作伙伴关系开发.
- 创建了13个由专家主导的按需网络研讨会,涵盖各种SUD主题.
- 利用有针对性的数字营销活动,并提供继续教育学分,以接触医疗保健专业人员和社区成员.
主要成果:
- 数字活动产生了800万次印象,达到140万个独特用户,点击率为0.10%.
- 苏达网站在推出三个月内吸引了3000多名独特访客.
- 发放了超过2948个持续教育学分小时,特定的人口统计和平板电脑用户的参与度很高.
结论:
- 苏达计划成功实施了一个可扩展的,数字化的教育计划,用于阿拉巴马州的苏达.
- 数字参与策略和持续教育激励措施在接触目标受众方面被证明是有效的.
- 未来的努力应优先考虑改善SUDs教育的获取和扩大对服务不足的人口的宣传.
相关概念视频
Community Based Intervention
264
Community-based interventions in mental health represent a paradigm shift from institution-centered care to treatments embedded within the fabric of local communities. By prioritizing inclusion and leveraging existing societal structures, this approach fosters a supportive environment conducive to addressing mental health challenges while promoting individual dignity and agency.
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
Foundations of Community Mental Health Programs
Central to the success of community-based interventions is the...
264
Substance Use Disorders Affecting Sleep
391
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
391
Models of Health Promotion and Illness Prevention II
2.0K
The person's health status fluctuates continually, varying from being in good health to becoming ill and returning to being healthy. To understand the concept of illness prevention, there are two models. First, the health-illness continuum model is a graphic representation of an individual's wellness. It states that a person is considered healthy in the absence of physical disease and the presence of good emotional health.
The agent-host-environment model states that disease results...
The agent-host-environment model states that disease results...
2.0K
Levels of Health Promotion and Illness Prevention
14.1K
Health promotion allows a person to control the determinants of health, resulting in an improved health status. It enhances the quality of life and reduces premature deaths. Health promotion and illness prevention programs help people make beneficial choices to reduce the risk of disease and disabilities. There are three health promotion and illness prevention levels: primary, secondary, and tertiary prevention.
In primary prevention, actions taken before disease onset prevent the disease from...
In primary prevention, actions taken before disease onset prevent the disease from...
14.1K
Drug Administration and Therapy Phases: Overview
1.2K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.2K


